in vitro News and Research

RSS

AspenBio Pharma closes underwritten public offering of 1,946,000 shares of common stock

AspenBio Pharma, Inc., an in vitro diagnostic company, today announced the closing of an underwritten public offering of 1,946,000 shares of common stock at an offering price of $2.10 per share.

21 Nov 2012

Novel technology can lead to more efficient and cheaper therapy for Pompe disease

VIB researchers from UGent and Vrije Universiteit Brussel , together with a team of the firm Oxyrane have developed a new technology that can lead to a more efficient and possibly also cheaper therapy for diseases such as Pompe disease. Oxyrane will now start developing a clinical program for this therapy in Pompe disease.

21 Nov 2012

KLF4 genetic factor prevents blood vessels from blockages

Researchers at Case Western Reserve University School of Medicine have identified a genetic factor that prevents blockages from forming in blood vessels, a discovery that could lead to new therapies for cardiovascular diseases.

20 Nov 2012

HORIBA Europe opens new R&D facility

HORIBA Europe has inaugurated its new research and technology center at the Saclay Technopole. Atsushi Horiba, President of the HORIBA Group, cut the ribbon opening the doors to HORIBA’s home for scientific innovation and cooperation.

19 Nov 2012

New insights into how MSCs ‘traffic’ from the circulation into tissues

Mesenchymal stem cells (MSCs), are a newly emerging cellular therapy being tested in approximately 250 clinical trials worldwide to help repair damaged tissues, such as injured heart muscle following a heart attack. The problem is that when culture-expanded MSCs are injected into the circulation, they have trouble gaining access to the inflamed tissues-exactly where their help is needed.

16 Nov 2012

New pathway appears to play a major role in information processing in the brain

Scientists at The Scripps Research Institute (TSRI) have identified a new pathway that appears to play a major role in information processing in the brain. Their research also offers insight into how imbalances in this pathway could contribute to cognitive abnormalities in humans.

16 Nov 2012

D737 compound restores motor function and longevity in fruit flies with Alzheimer's

An efficient, high-volume technique for testing potential drug treatments for Alzheimer's disease uncovered an organic compound that restored motor function and longevity to fruit flies with the disease, according to new research that could help put the search for an effective Alzheimer's drug on a faster track.

16 Nov 2012

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Myasthenia gravis (MG) is an autoimmune disease that produces weakness and fatiguability of muscles. It affects between 1 and 7 people per 10,000, according to the best statistics.

15 Nov 2012

AspenBio Pharma provides clinical and business update for third quarter 2012

AspenBio Pharma, Inc., an in vitro diagnostic company, today provided a clinical and business update for the third quarter 2012. The Company reported it has started the hospital training phase of its pivotal U.S. clinical study and remains on track to initiate patient enrollment before the end of the year.

13 Nov 2012

Sprucing up treatment for fungal nail infection

A lacquer containing resin from the Norway spruce shows promise as a treatment for onychomycosis, suggest results from an exploratory study.

9 Nov 2012

Boulder Diagnostics launches novel SpiroFind test to detect Lyme disease

Boulder Diagnostics Inc. announced today the European market launch of the CE marked SpiroFind in vitro diagnostic test for the detection of active Lyme Borreliosis. The SpiroFind test is offered as a diagnostic service by the company's clinical diagnostic service laboratory in Mellrichstadt, Germany.

9 Nov 2012

Antibiotic choices critical for elderly with bloodstream infections

Failure to treat patients with bacteremia with an appropriate antibiotic is particularly harmful in elderly patients, report researchers.

8 Nov 2012

Pevion launches Defensomes platform for broad spectrum immune enhancement

Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. Defensomes offer opportunities for a wide range of prophylactic and therapeutic indications, where boosting of the body's own natural defense is beneficial.

8 Nov 2012

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Aileron Therapeutics, Inc. and its collaborator Roche today announced new results of a preclinical study of its Stapled Peptide oncology drug candidate ATSP-7041, which exhibited robust efficacy in MDM2 and MDMX xenograft cancer models.

8 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

LipoScience presents key findings related to LDL-P and CVD at AHA annual meeting

LipoScience, Inc., an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases, today presented key findings related to lipoprotein particles (LDL-P) and cardiovascular disease at the Annual Meeting of the American Heart Association (AHA) in Los Angeles.

7 Nov 2012

New test device allows 'more real-life modeling' of contact lens wear

Modern contact lens materials are prone to drying when exposed to air, which contributes to the buildup of deposits on contact lenses, according to a study - "The Impact of Intermittent Air Exposure on Lipid Deposition", appearing in the November issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

6 Nov 2012

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have led a study published in PLoS One showing that the inhibition of a family member of NADPH oxidase enzyme, NOX4, plays an important role in liver fibrosis.

5 Nov 2012

Affymetrix reports net loss of $17.9 million for third quarter 2012

Affymetrix, Inc., today reported its operating results for the third quarter of 2012. Total revenue for the quarter was $79.6 million, including approximately $17.6 million in revenue from eBioscience during the third quarter of 2012. This compares to total revenue of $64.0 million for the same period of 2011.

5 Nov 2012

Link between ChemoFx Drug Response Marker results and RFS of cervical cancer patients

A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.

2 Nov 2012